Publicaciones (56) Publicaciones en las que ha participado algún/a investigador/a

2018

  1. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

    Cell, Vol. 175, Núm. 2, pp. 313-326

  2. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

    Nature Communications, Vol. 9, Núm. 1

  3. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432

  4. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  5. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

  6. Are phase I trials safe for older patients?

    Journal of Geriatric Oncology, Vol. 9, Núm. 2, pp. 87-92

  7. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128

  8. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

    European Urology, Vol. 73, Núm. 3, pp. 462-468

  9. Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography

    Journal of Proteome Research, Vol. 17, Núm. 3, pp. 1172-1182

  10. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

    Clinical Genitourinary Cancer, Vol. 16, Núm. 6, pp. e1133-e1139

  11. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

    Breast Journal, Vol. 24, Núm. 4, pp. 473-479

  12. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  13. Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    OncoImmunology, Vol. 7, Núm. 1

  14. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460

  15. Early-drug development in the era of immuno-oncology: Are we ready to face the challenges?

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1727-1740

  16. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

    Clinical Colorectal Cancer, Vol. 17, Núm. 4, pp. e617-e629

  17. Ent cobra ontology: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy)

    Journal of Contemporary Brachytherapy, Vol. 10, Núm. 3, pp. 260-266

  18. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer

    Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629

  19. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

  20. High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease

    Oncotarget, Vol. 9, Núm. 31, pp. 21893-21903